This Market Spotlight report covers the Ischemic Stroke market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, licensing and asset acquisition deals, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.

Key Takeaways

• Datamonitor Healthcare estimates that in 2021, there were approximately 82.3 million prevalent cases of ischemic stroke worldwide, and forecasts that number to increase to 87.5 million prevalent cases by 2029.
• The approved drugs in the ischemic stroke space focus on a wide variety of targets. Most approved drugs are administered orally, with the remainder being available in intravenous, subcutaneous, and sublingual/oral transmucosal formulations.
• The majority of industry-sponsored drugs in active clinical development for ischemic stroke are in Phase II. Therapies in active clinical development for ischemic stroke focus on a wide variety of targets and include small molecules, peptides, and cell-based therapies.
• High-impact upcoming events for drugs in the ischemic stroke space comprise topline Phase II trial results for Milvexian, topline Phase III trial results for Cirara, and an expected PDUFA date for HPC-Cord Blood.
• The overall likelihood of approval of a Phase I ischemic stroke asset is 0.9%, and the average probability a drug advances from Phase III is 11.1%. Drugs, on average, take 13.1 years from Phase I to approval, compared to 10.2 years in the overall neurology space.
• The distribution of clinical trials across Phase I–IV indicates that the majority of trials for stroke have been in the early and midphases of development, with 70% of trials in Phase I–II, and 30% in Phase III–IV.
• The US has a substantial lead in the number of stroke clinical trials globally. Germany leads the major European markets, while China has the top spot in Asia.
• Clinical trial activity in the stroke space is dominated by completed trials. Mitsubishi Tanabe has the highest number of completed clinical trials for stroke, with 15 trials.
• Boehringer Ingelheim and Roche lead industry sponsors with the highest overall number of clinical trials for stroke.